• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见遗传疾病:新型治疗策略及对人类生物学的见解

Rare Genetic Disorders: Novel Treatment Strategies and Insights Into Human Biology.

作者信息

Koch Peter J, Koster Maranke I

机构信息

Department of Anatomy and Cell Biology, Brody School of Medicine (BSOM) at East Carolina University (ECU), Greenville, NC, United States.

出版信息

Front Genet. 2021 Aug 6;12:714764. doi: 10.3389/fgene.2021.714764. eCollection 2021.

DOI:10.3389/fgene.2021.714764
PMID:34422015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8378213/
Abstract

The last decade has seen a dramatic increase in innovative ideas for the treatment of genetic disorders for which no curative therapies exist. Gene and protein replacement therapies stand out as novel approaches to treat a select group of these diseases, such as certain tissue fragility disorders. Further, the advent of stem cell approaches, such as induced pluripotent stem cells (iPSC) technology, has led to the development of new methods of creating replacement tissues for regenerative medicine. This coincided with the discovery of genome editing techniques, which allow for the correction of disease-causing mutations. The culmination of these discoveries suggests that new and innovative therapies for monogenetic disorders affecting single organs or tissues are on the horizon. Challenges remain, however, especially with diseases that simultaneously affect several tissues and organs during development. Examples of this group of diseases include ectodermal dysplasias, genetic disorders affecting the development of tissues and organs such as the skin, cornea, and epithelial appendages. Gene or protein replacement strategies are unlikely to be successful in addressing the multiorgan phenotype of these diseases. Instead, we believe that a more effective approach will be to focus on correcting phenotypes in the most severely affected tissues. This could include the generation of replacement tissues or the identification of pharmaceutical compounds that correct disease pathways in specific tissues.

摘要

在过去十年中,对于尚无治愈疗法的遗传性疾病的创新治疗理念急剧增加。基因和蛋白质替代疗法作为治疗其中某些特定疾病(如某些组织脆性疾病)的新方法脱颖而出。此外,干细胞方法的出现,如诱导多能干细胞(iPSC)技术,已促使再生医学中用于创建替代组织的新方法得以发展。这与基因组编辑技术的发现同时发生,基因组编辑技术能够纠正致病突变。这些发现的 culmination 表明,针对影响单一器官或组织的单基因疾病的新型创新疗法即将出现。然而,挑战依然存在,尤其是对于那些在发育过程中同时影响多个组织和器官的疾病。这类疾病的例子包括外胚层发育异常,即影响皮肤、角膜和上皮附属器等组织和器官发育的遗传性疾病。基因或蛋白质替代策略在解决这些疾病的多器官表型方面不太可能成功。相反,我们认为更有效的方法是专注于纠正受影响最严重组织中的表型。这可能包括生成替代组织或鉴定能够纠正特定组织中疾病途径的药物化合物。

相似文献

1
Rare Genetic Disorders: Novel Treatment Strategies and Insights Into Human Biology.罕见遗传疾病:新型治疗策略及对人类生物学的见解
Front Genet. 2021 Aug 6;12:714764. doi: 10.3389/fgene.2021.714764. eCollection 2021.
2
Next generation human skin constructs as advanced tools for drug development.下一代人造皮肤构建体作为药物开发的先进工具。
Exp Biol Med (Maywood). 2017 Nov;242(17):1657-1668. doi: 10.1177/1535370217712690. Epub 2017 Jun 7.
3
Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications.基于 iPSC 的疾病建模的当前挑战及其治疗意义。
Cells. 2019 Apr 30;8(5):403. doi: 10.3390/cells8050403.
4
Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.利用患者特异性干细胞模型推进神经精神疾病的药物研发。
Mol Cell Neurosci. 2016 Jun;73:104-15. doi: 10.1016/j.mcn.2016.01.011. Epub 2016 Jan 28.
5
Gene correction in patient-specific iPSCs for therapy development and disease modeling.用于治疗开发和疾病建模的患者特异性诱导多能干细胞中的基因校正。
Hum Genet. 2016 Sep;135(9):1041-58. doi: 10.1007/s00439-016-1691-5. Epub 2016 Jun 2.
6
Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models.利用多能干细胞疾病模型解析遗传性心肌病的生物学机制
Curr Cardiol Rep. 2017 Apr;19(4):30. doi: 10.1007/s11886-017-0842-1.
7
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.利用多能干细胞技术对人类神经退行性疾病进行逆向工程研究。
Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28.
8
Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders.血液系统疾病中诱导多能干细胞的最新进展
Stem Cells Int. 2019 May 2;2019:5171032. doi: 10.1155/2019/5171032. eCollection 2019.
9
Generation of human organs in pigs via interspecies blastocyst complementation.通过种间囊胚互补在猪体内生成人体器官。
Reprod Domest Anim. 2016 Oct;51 Suppl 2:18-24. doi: 10.1111/rda.12796.
10
Oral Mucosa-Derived Induced Pluripotent Stem Cells from Patients with Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome.来自裂指(趾)-外胚层发育不良-腭裂综合征患者的口腔黏膜源性诱导多能干细胞。
Cell Reprogram. 2018 Aug;20(4):215-224. doi: 10.1089/cell.2017.0064. Epub 2018 Jul 10.

引用本文的文献

1
Moral judgment of genetic technologies: validation of the genetic technologies questionnaire in the German-speaking population.基因技术的道德判断:德语区人群中基因技术问卷的验证
Front Genet. 2025 Aug 1;16:1620962. doi: 10.3389/fgene.2025.1620962. eCollection 2025.
2
Poly(lactide)-Based Materials Modified with Biomolecules: A Review.生物分子修饰的聚丙交酯基材料综述
Materials (Basel). 2024 Oct 24;17(21):5184. doi: 10.3390/ma17215184.
3
Ectodermal dysplasias: New perspectives on the treatment of so far immedicable genetic disorders.

本文引用的文献

1
Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?PRIMA-1 和 PRIMA-1(APR246)在血液系统恶性肿瘤中的抗肿瘤作用:仍然是突变型 P53 依赖性事件吗?
Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098.
2
Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1/APR-246.PRIMA-1/APR-246 改善严重皮肤糜烂的急性放射性皮肤损伤患者的表皮覆盖。
Cell Death Dis. 2020 Jan 16;11(1):30. doi: 10.1038/s41419-020-2223-8.
3
CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
外胚层发育异常:治疗迄今无法治愈的遗传性疾病的新视角。
Front Genet. 2022 Sep 6;13:1000744. doi: 10.3389/fgene.2022.1000744. eCollection 2022.
4
Differentiation of Human Induced Pluripotent Stem Cells into Keratinocytes.人诱导多能干细胞向角质细胞的分化。
Curr Protoc. 2022 Apr;2(4):e408. doi: 10.1002/cpz1.408.
基于CRISPR/Cas9的靶向基因组编辑,利用诱导多能干细胞纠正隐性营养不良性大疱性表皮松解症。
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26846-26852. doi: 10.1073/pnas.1907081116. Epub 2019 Dec 9.
4
P63-related disorders: Dermatological characteristics in 22 patients.P63 相关疾病:22 例患者的皮肤科特征。
Exp Dermatol. 2019 Oct;28(10):1190-1195. doi: 10.1111/exd.14045.
5
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.用于隐性营养不良型大疱性表皮松解症的基因校正自体细胞治疗的 1/2a 期临床试验。
JCI Insight. 2019 Oct 3;4(19):130554. doi: 10.1172/jci.insight.130554.
6
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.估算罕见病的累计点患病率:对孤儿药数据库的分析。
Eur J Hum Genet. 2020 Feb;28(2):165-173. doi: 10.1038/s41431-019-0508-0. Epub 2019 Sep 16.
7
Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa.临床复发性皮肤的培养表皮自体移植作为隐性营养不良型大疱性表皮松解症的潜在伤口治疗方法。
J Invest Dermatol. 2019 Oct;139(10):2115-2124.e11. doi: 10.1016/j.jid.2019.03.1155. Epub 2019 May 2.
8
Ankyloblepharon-ectodermal dysplasia-clefting syndrome misdiagnosed as epidermolysis bullosa and congenital ichthyosiform erythroderma: Case report and review of published work.睑-外胚层发育不良-裂腭综合征误诊为大疱性表皮松解症和先天性鱼鳞红皮病:病例报告和文献复习。
J Dermatol. 2019 May;46(5):422-425. doi: 10.1111/1346-8138.14837. Epub 2019 Feb 27.
9
Ectodermal dysplasias: Classification and organization by phenotype, genotype and molecular pathway.外胚层发育不全:按表型、基因型和分子途径分类和组织。
Am J Med Genet A. 2019 Mar;179(3):442-447. doi: 10.1002/ajmg.a.61045. Epub 2019 Jan 31.
10
Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia.X 连锁性少汗型外胚层发育不良的产前矫正。
N Engl J Med. 2018 Apr 26;378(17):1604-1610. doi: 10.1056/NEJMoa1714322.